Form 4: Integrated BioPharma Co-CEO Exercises Stock Options, Acquires 55,555 Shares

Christina Kay, Co-Chief Executive Officer of Integrated BioPharma Inc., exercised stock options to acquire 55,555 common shares at $0.09 per share.

Summary

• Christina Kay, the Co-Chief Executive Officer of Integrated BioPharma Inc., exercised stock options on November 25, 2024.
• This transaction resulted in the acquisition of 55,555 common stock shares at a price of $0.09 per share.
• Following this transaction, Ms. Kay directly owns 1,329,022 common shares.
• The stock options were granted on June 2, 2015, and were exercisable until June 2, 2025.
• Ms. Kay also holds 144,445 derivative securities (stock options) after this transaction.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider transaction, which is neither positive nor negative in itself. It is a neutral event.

Positives

• The exercise of stock options by a top executive can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option exercises are a common form of executive compensation in publicly traded companies.
• The reporting of these transactions via SEC Form 4 is a standard practice to ensure transparency and prevent insider trading.
• The specific details of the option grant and exercise are unique to Integrated BioPharma and its compensation policies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows confidence from the Co-CEO.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, common stock, executive compensation, Integrated BioPharma, INBP